Mirum Pharmaceuticals’ LIVMARLI (maralixibat) Approved by the European Commission for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome Two Months and OlderDec 13, 2022- First and only medication approved in both the U.S. and Europe to treat cholestatic pruritus in patients with Alagille.